Understanding how a bacterial toxin damages DNA and its link to cancer
Molecular Basis for the Two-Stage Disassembly of Cytolethal Distending Toxin
This study is looking at how a toxin from certain bacteria can harm DNA in human cells, which might lead to cancer, and it's for anyone interested in understanding how this process works so we can find better ways to treat toxin-related cancers.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Central Florida NIH-funded |
| Lab location | 1 site (Orlando, United States) |
| Project ID | NIH-11114069 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms by which the cytolethal distending toxin (CDT) from certain bacteria damages DNA in human cells, potentially leading to cancer. The project focuses on the two-stage disassembly process of the toxin, which involves the separation of its components as it moves through the cell. By studying how the toxin enters cells and interacts with cellular structures, researchers aim to uncover critical details about its function and the conditions that activate its harmful effects. This knowledge could provide insights into the development of new therapeutic strategies against toxin-related cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers linked to bacterial infections or those interested in the molecular mechanisms of cancer development.
Not a fit: Patients with cancers not associated with bacterial toxins or those without any cancer diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment options for cancers associated with bacterial infections.
How similar studies have performed: While the specific two-stage mechanism of CDT is novel, similar research on bacterial toxins has shown promise in understanding their roles in cancer development.
Where this research is happening
Orlando, United States
- University of Central Florida — Orlando, United States (Active)
Researchers
- Principal investigator: Teter, Kenneth R — University of Central Florida
- Study coordinator: Teter, Kenneth R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.